Research
Hormonal
Semaglutide slows the progression of chronic kidney disease (CKD) and reduces major kidney disease events in patients with type 2 diabetes.
If you have type 2 diabetes and chronic kidney disease, ask your doctor about semaglutide. It is a once-weekly injection that has been proven to significantly slow the progression of kidney disease and reduce the risk of major kidney events.
StrongSupportsHIGH confidence
Similarly, the FLOW trial showed a 24% reduction in major kidney disease events (HR 0.76; 95% CI: 0.66–0.88; p = 0.002) with weekly 1.0 mg semaglutide in individuals with T2D with CKD.
Why this rating
Based on the FLOW trial, a large RCT with statistically significant results.
Source
Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome
Richard J. MacIsaac · Future Cardiology · 2025
narrative_reviewCited 11×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →